Specifically, Barasertib, a selective Aurora kinase B inhibitor, has shown promise in inducing apoptosis in multiple SCLC cell lines, and inhibit tumor growth in mouse xenograft models with cMYC amplification [131]. Here, MYC is linked to small cell lung carcinoma.